explain why voriconazole may be effective in the treatment of mycoses like trichosporonosis that do not respond to other azoles. According to a new study, voriconazole is "superior" to amphotericin B for treating life-threatening invasive aspergillosis (2) and was recently approved in some European countries for the treatment of invasive aspergillosis.
In our previous paper (7) we emphasized the importance of the patient's basic immune status in determining the outcome of T. asahii infection. We concluded that in vitro resistance to antifungal drugs might not be critical in immunocompetent patients. However, immunocompromised patients may be dependent on fungicidal drug activity, so that infection with multidrug-resistant T. asahii isolates may be fatal in this population. Our new data with the low MICs and MFCs of voriconazole that confirm other in vitro studies suggest that voriconazole may offer a clinical solution in trichosporonosis when other antifungal drugs fail. 
